FDA Implementing New CMC Review Process Through Revamped Office
Executive Summary
FDA is changing its review of chemistry, manufacturing and controls submissions with a new quality assessment office that will involve greater staff specialization
You may also be interested in...
OTR acting director
FDA Office of Testing & Research Division of Pharmaceutical Analysis Director Cindy Buhse succeeds Ajaz Hussain as OTR acting director effective Oct. 31. Buhse has worked at the agency since 2001. Hussain, who also served as deputy director of the Office of Pharmaceutical Science, left FDA Oct. 28 to become VP-biopharmaceutical development at Sandoz (1"The Pink Sheet" Oct. 10, 2005, p. 3)...
Quality By Design Could Be Used To Reduce Alcohol-Induced Dose Dumping
Quality by design principles could be used to create "rugged" formulations that are less likely to be subject to alcohol-induced dose dumping, FDA and members of its Advisory Committee for Pharmaceutical Science said at an Oct. 26 meeting
OTR acting director
FDA Office of Testing & Research Division of Pharmaceutical Analysis Director Cindy Buhse succeeds Ajaz Hussain as OTR acting director effective Oct. 31. Buhse has worked at the agency since 2001. Hussain, who also served as deputy director of the Office of Pharmaceutical Science, left FDA Oct. 28 to become VP-biopharmaceutical development at Sandoz (1"The Pink Sheet" Oct. 10, 2005, p. 3)...